PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES
The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this inv...
Saved in:
Main Authors | , , , , , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
21.04.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I:or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A:or a pharmaceutically acceptable salt, wherein the variables are as defined herein. |
---|---|
AbstractList | The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I:or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A:or a pharmaceutically acceptable salt, wherein the variables are as defined herein. |
Author | DAVIS, Chris FRAYSSE, Damine DAVIS, Rebecca BOYALL, Dean DURRANT, Steven MIDDLETON, Donald ODONNELL, Michael STORCK, Pierre-Henri JIMENEZ, Juan-Miguel ETXEBARRIA I JARDI, Gorka TWIN, Heather PANESAR, Maninder STUDLEY, John AHMAD, Nadia PINDER, Joanne SHAW, David CHARRIER, Jean-Damien KAY, David PIERARD, Francoise KNEGTEL, Roland |
Author_xml | – fullname: PIERARD, Francoise – fullname: KAY, David – fullname: JIMENEZ, Juan-Miguel – fullname: ODONNELL, Michael – fullname: KNEGTEL, Roland – fullname: TWIN, Heather – fullname: CHARRIER, Jean-Damien – fullname: STORCK, Pierre-Henri – fullname: AHMAD, Nadia – fullname: DURRANT, Steven – fullname: PINDER, Joanne – fullname: STUDLEY, John – fullname: BOYALL, Dean – fullname: PANESAR, Maninder – fullname: SHAW, David – fullname: FRAYSSE, Damine – fullname: MIDDLETON, Donald – fullname: ETXEBARRIA I JARDI, Gorka – fullname: DAVIS, Chris – fullname: DAVIS, Rebecca |
BookMark | eNqNissKgkAUQGdRi17_cD8gIbHIlje9g5d0RmbGRUWIxbQKFez_yaAPaHU4nDMXk7Zr_Uzcy7PBi871NVzvAryNygWnrMhCZUlWOaAFVhkf2WljQUtAZ-DECi2B1AZcRuAMoStIuW9PUCVkIGVL42OXYvpsXoNf_bgQIMklWeD7rvZD3zx86981lVG8iffbA4bRH8sH4qs1ag |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | PYRAZOLO[1,5-A]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASE D'ATR POUR LE TRAITEMENT DES MALADIES DE CANCER PYRAZOLO[1,5-A]PYRIMIDINE ALS ATR-KINASE-INHIBITOREN NÜTZLICHE VERBINDUNGEN ZUR BEHANDLUNG VON KREBSERKRANKUNGEN |
ExternalDocumentID | EP3808749A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_EP3808749A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 12:47:18 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French German |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_EP3808749A13 |
Notes | Application Number: EP20200198773 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210421&DB=EPODOC&CC=EP&NR=3808749A1 |
ParticipantIDs | epo_espacenet_EP3808749A1 |
PublicationCentury | 2000 |
PublicationDate | 20210421 |
PublicationDateYYYYMMDD | 2021-04-21 |
PublicationDate_xml | – month: 04 year: 2021 text: 20210421 day: 21 |
PublicationDecade | 2020 |
PublicationYear | 2021 |
RelatedCompanies | Vertex Pharmaceuticals Incorporated |
RelatedCompanies_xml | – name: Vertex Pharmaceuticals Incorporated |
Score | 3.328425 |
Snippet | The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210421&DB=EPODOC&locale=&CC=EP&NR=3808749A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NS8MwFA9jinrTqTi_yEF6srhm7dochmRtSivbWtpOpiKj6VrYpRuu4r_vS9mmF73li0fy4OXll_eF0J2Z60YhLKEaWc9Q9UIzVNCKQqUkJbRDrXlKZezwaNzzJvrT1Jg20GIbC1PnCf2qkyOCRGUg71V9X69-PrGc2rdy_SAWMLR8dJO-o2zQMeAXnWiKM-jzMHACW7FtaCnjqN-1OpapUwZAaQ9e0aYUBv48kEEpq98axT1G-yEQK6sT1MjLFjq0t4XXWuhgtLF3Q3MjeutTJMKXiL0Gw-BNuzdU9g5duHccWTQDT2LuToaYxdgfe_7AT4IoxoGLWRJhgOcs5hjAHk48jpOIs0Qm8JfztqxME2HHjzmsic8QdnlieypsdrZjzIyHu2N1z1GzXJb5BcKaKVLgMBFUEFlPOtWLrNsp5kR6mmYmbaP2n2Qu_5m7QkeSw9KUQrRr1Kw-PvMb0MiVuK15-Q1XH4fz |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT4MwFG-WaZw3nRrnZw-Gk8TBYMBhMQxKQBkQ6Mx0MQtlkOzCFofx3_eVbNOL3vqVl_Ylr6-_vi-E7rRcUQumM1HN-qqoFJIqglZkoiGnstE19Hlq8NjhUdB3x8rTRJ000GIbC1PnCf2qkyOCRGUg71V9X69-PrHs2rdy_cAWMLR8dOjAFjboGPCLIkuCPRyQKLRDS7AsaAlBPOjpXV1TDBOA0h68sDUuDORlyINSVr81inOE9iMgVlbHqJGXbdSytoXX2uhgtLF3Q3MjeusTxKLX2HwL_XAq3aui-Q5duHdsXjQDjxPijH1sJtgLXG_o0TBOcOhgk8YY4LmZEAxgD1OXYBoTk_IE_nze4pVpYmx7CYE1ySnCDqGWK8JmZzvGzEi0O1bvDDXLZZmfIyxpLAUOy8xgMq8nnSpF1usWc5l7mmaa0UGdP8lc_DN3i1ouHfkz3wueL9Eh5zY3q8jSFWpWH5_5NWjnit3UfP0G5EeK5g |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PYRAZOLO%5B1%2C5-A%5DPYRIMIDINES+USEFUL+AS+INHIBITORS+OF+ATR+KINASE+FOR+THE+TREATMENT+OF+CANCER+DISEASES&rft.inventor=PIERARD%2C+Francoise&rft.inventor=KAY%2C+David&rft.inventor=JIMENEZ%2C+Juan-Miguel&rft.inventor=ODONNELL%2C+Michael&rft.inventor=KNEGTEL%2C+Roland&rft.inventor=TWIN%2C+Heather&rft.inventor=CHARRIER%2C+Jean-Damien&rft.inventor=STORCK%2C+Pierre-Henri&rft.inventor=AHMAD%2C+Nadia&rft.inventor=DURRANT%2C+Steven&rft.inventor=PINDER%2C+Joanne&rft.inventor=STUDLEY%2C+John&rft.inventor=BOYALL%2C+Dean&rft.inventor=PANESAR%2C+Maninder&rft.inventor=SHAW%2C+David&rft.inventor=FRAYSSE%2C+Damine&rft.inventor=MIDDLETON%2C+Donald&rft.inventor=ETXEBARRIA+I+JARDI%2C+Gorka&rft.inventor=DAVIS%2C+Chris&rft.inventor=DAVIS%2C+Rebecca&rft.date=2021-04-21&rft.externalDBID=A1&rft.externalDocID=EP3808749A1 |